Aeglea Bio Therapeutics Inc (AGLE)

NASDAQ
4.200
-0.160(-3.67%)
  • Volume:
    106,453
  • Bid/Ask:
    0.000/0.000
  • Day's Range:
    4.200 - 4.440

AGLE Overview

Prev. Close
4.36
Day's Range
4.2-4.44
Revenue
15.1M
Open
4.44
52 wk Range
3.47-8.79
EPS
-1.27
Volume
106,453
Market Cap
208.13M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
333,568
P/E Ratio
-
Beta
1.42
1-Year Change
-42.93%
Shares Outstanding
49,319,958
Next Earnings Date
Mar 16, 2022
What is your sentiment on Aeglea Bio Therapeutics Inc?
or
Market is currently closed. Voting is open during market hours.

Aeglea Bio Therapeutics Inc Company Profile

Employees
90

Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing human enzyme therapeutics to benefit people with rare metabolic diseases. The Company’s product candidates include pegzilarginase and AGLE-177. The Company's lead product candidate, pegzilarginase, is a recombinant human arginase one that enzymatically degrades the amino acid arginine to lower arginine levels in patients with Arginase one Deficiency. Its engineered pegzilarginase with modifications that enhance the stability and arginine-degrading activity of the enzyme in human plasma. The Company is evaluating Pegzilarginase in a global pivotal Phase III PEACE (Pegzilarginase Effect on Arginase one Deficiency Clinical Endpoints) trial and in a Phase II open-label extension study for patients with Arginase One Deficiency. Its AGLE-177, is a novel PEGylated, or polyethylene glycol modified, human enzyme engineered to reduce Homocystinuria.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.